Table 3.

Patients with a ≥ 2-step and ≥ 3-step improvement or worsening at Weeks 52 and 100 from baseline

	IVT-AFL fixed n/N (%)	IVT-AFL T&E n/N (%)	IVT-AFL PRN n/N (%)
Week 52
≥ 2-step improvement	6/135 (4.4)	7/141 (5.0)	5/132 (3.8)
≥ 3-step improvement	3/135 (2.2)	0/141 (0.0)	0/132 (0.0)
≥ 2-step worsening	8/128 (6.3)	4/131 (3.1)	7/127 (5.5)
≥ 3-step worsening	3/128 (2.3)	1/131 (0.8)	4/127 (3.1)
Week 100a
≥ 2-step improvement	9/128 (7.0)	7/131 (5.3)	3/127 (2.4)
≥ 3-step improvement	4/128 (3.1)	3/131 (2.3)	0/127 (0.0)
≥ 2-step worsening	8/128 (6.3)	4/131 (3.1)	7/127 (5.5)
≥ 3-step worsening	3/128 (2.3)	1/131 (0.8)	4/127 (3.1)

Observed cases. Patients had previously received 1 year of IVT-AFL treatment prior to the VIOLET study baseline

IVT-AFL intravitreal aflibercept, PRN pro re nata, T&E treat-and-extend

^aN = 386